Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
Laure GossecVibeke StrandClare ProudfootChieh-I ChenSophie GuillonneauToshio KimuraHubert van HoogstratenErin ManganMatthew ReaneyPublished in: The Journal of rheumatology (2019)
Based on the RAID, sarilumab + csDMARD or as monotherapy reduced the effect of RA on patients' lives to a greater extent than placebo + csDMARD or ADA monotherapy. (ClinicalTrials.gov: NCT01709578 and NCT02332590).
Keyphrases
- rheumatoid arthritis
- end stage renal disease
- newly diagnosed
- ejection fraction
- chronic kidney disease
- prognostic factors
- disease activity
- peritoneal dialysis
- randomized controlled trial
- ankylosing spondylitis
- open label
- systemic lupus erythematosus
- combination therapy
- systemic sclerosis
- interstitial lung disease
- patient reported outcomes